Genmab A/S - Asset Resilience Ratio

Latest as of September 2025: 23.50%

Genmab A/S (GMAB) has an Asset Resilience Ratio of 23.50% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Genmab A/S balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Dkr1.65 Billion

≈ $258.15 Million USD Cash + Short-term Investments

Total Assets

Dkr7.02 Billion

≈ $1.10 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2004–2024)

This chart shows how Genmab A/S's Asset Resilience Ratio has changed over time. See Genmab A/S (GMAB) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Genmab A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Genmab A/S stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Dkr0.00	0%
Short-term Investments	Dkr1.65 Billion	23.5%
Total Liquid Assets	Dkr1.65 Billion	23.50%

Asset Resilience Insights

Good Liquidity Position: Genmab A/S maintains a healthy 23.50% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Genmab A/S Industry Peers by Asset Resilience Ratio

Compare Genmab A/S's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Argen-X F:1AE	Biotechnology	25.67%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.21%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.48%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	70.49%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for Genmab A/S (2004–2024)

The table below shows the annual Asset Resilience Ratio data for Genmab A/S.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	24.54%	Dkr11.24 Billion ≈ $1.76 Billion	Dkr45.81 Billion ≈ $7.17 Billion	-13.06pp
2023-12-31	37.60%	Dkr13.27 Billion ≈ $2.08 Billion	Dkr35.29 Billion ≈ $5.52 Billion	-3.67pp
2022-12-31	41.27%	Dkr12.43 Billion ≈ $1.94 Billion	Dkr30.12 Billion ≈ $4.71 Billion	-0.88pp
2021-12-31	42.15%	Dkr10.38 Billion ≈ $1.62 Billion	Dkr24.63 Billion ≈ $3.85 Billion	+0.44pp
2020-12-31	41.71%	Dkr8.82 Billion ≈ $1.38 Billion	Dkr21.14 Billion ≈ $3.31 Billion	-7.28pp
2019-12-31	48.99%	Dkr7.42 Billion ≈ $1.16 Billion	Dkr15.14 Billion ≈ $2.37 Billion	-16.88pp
2018-12-31	65.87%	Dkr5.57 Billion ≈ $871.97 Million	Dkr8.46 Billion ≈ $1.32 Billion	+4.15pp
2017-12-31	61.72%	Dkr4.08 Billion ≈ $637.59 Million	Dkr6.60 Billion ≈ $1.03 Billion	-7.29pp
2016-12-31	69.01%	Dkr3.61 Billion ≈ $565.58 Million	Dkr5.24 Billion ≈ $819.56 Million	+1.89pp
2015-12-31	67.12%	Dkr2.62 Billion ≈ $409.80 Million	Dkr3.90 Billion ≈ $610.58 Million	-13.17pp
2014-12-31	80.28%	Dkr2.30 Billion ≈ $360.08 Million	Dkr2.87 Billion ≈ $448.51 Million	+0.07pp
2013-12-31	80.21%	Dkr1.39 Billion ≈ $217.29 Million	Dkr1.73 Billion ≈ $270.91 Million	-4.66pp
2012-12-31	84.87%	Dkr1.44 Billion ≈ $224.79 Million	Dkr1.69 Billion ≈ $264.86 Million	+18.69pp
2011-12-31	66.19%	Dkr1.04 Billion ≈ $162.00 Million	Dkr1.56 Billion ≈ $244.77 Million	+3.79pp
2010-12-31	62.39%	Dkr1.55 Billion ≈ $242.24 Million	Dkr2.48 Billion ≈ $388.26 Million	+25.62pp
2009-12-31	36.77%	Dkr816.91 Million ≈ $127.81 Million	Dkr2.22 Billion ≈ $347.58 Million	-15.15pp
2008-12-31	51.92%	Dkr1.69 Billion ≈ $264.73 Million	Dkr3.26 Billion ≈ $509.89 Million	-38.05pp
2007-12-31	89.97%	Dkr3.56 Billion ≈ $557.25 Million	Dkr3.96 Billion ≈ $619.38 Million	+18.20pp
2006-12-31	71.77%	Dkr1.30 Billion ≈ $202.65 Million	Dkr1.80 Billion ≈ $282.35 Million	+8.18pp
2005-12-31	63.60%	Dkr871.56 Million ≈ $136.36 Million	Dkr1.37 Billion ≈ $214.41 Million	+5.51pp
2004-12-31	58.09%	Dkr738.86 Million ≈ $115.60 Million	Dkr1.27 Billion ≈ $199.00 Million	--

pp = percentage points

About Genmab A/S

CO:GMAB Denmark Biotechnology

Market Cap

$16.33 Billion

Dkr104.35 Billion DKK

Market Cap Rank

#1511 Global

#8 in Denmark

Share Price

Dkr1694.00

Change (1 day)

+0.24%

52-Week Range

Dkr1270.00 - Dkr2251.00

All Time High

Dkr3295.00